Key Takeaways From AtriCure Analyst Ratings
Portfolio Pulse from Benzinga Insights
AtriCure (NASDAQ:ATRC) was analyzed by 6 analysts, showing a mix of bullish and somewhat bullish ratings with no bearish or indifferent stances. The average 12-month price target is now $52.00, down from $59.00, with a high estimate of $60.00 and a low of $44.00. Analysts from Needham and JMP Securities have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. AtriCure specializes in surgical treatments for atrial fibrillation and related conditions, with a majority of revenue from the U.S. The company has shown strong revenue growth, net margin, ROE, and ROA, with a low debt-to-equity ratio.
January 04, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AtriCure's analyst ratings are mostly bullish, with a decrease in the average price target to $52.00. The company's strong financial metrics may support positive investor sentiment.
The mixed analyst ratings with a downward adjustment in price targets suggest a cautious optimism. The strong financial performance indicators like revenue growth, net margin, ROE, and ROA, along with a low debt-to-equity ratio, could mitigate the impact of the lowered price target. However, the reduction in the average price target may temper short-term stock price growth, leading to a neutral score.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100